Daiichi Sankyo Europe GmbH: First-in-class cholesterol-lowering treatment NILEMDO? and its combination with ezetimibe, NUSTENDI?, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk

NILEMDO? (bempedoic acid), a first-in-class, oral treatment and NUSTENDI? (bempedoic acid ezetimibe fixed-dose combination) receive label update approval from the European Commission as treatments

Related Keywords

Italy ,Milan ,Lombardia ,United Kingdom ,Turkey ,Switzerland ,Daiichi Sankyo Europe Gmb ,Sheldon Koenig ,Alberico Catapano ,Gillian Dsouza ,Daiichi Sankyo ,Oliver Appelhans ,Daiichi Sankyo Europe ,University Of Milan ,European Atherosclerosis Society ,European Society Of Cardiology ,European Medicines Agency ,European Commission ,Head Of Europe Specialty Division ,Esperion Therapeutics Inc ,European Commissionas ,Sankyo Europe Gmbh ,Esperion Therapeutics ,Europe Specialty Division ,Professor Alberico Catapano ,Cholesterol Lowering ,Bempedoic Acid ,Inhibiting Regimen ,Sankyo Europe ,European Economic Area ,Marketing Authorisation Holder ,Task Force ,European Society ,Cardiovascular Disease Statistics ,Cardiovascular Outcomes ,Public Relations ,Specialty Medicines ,Ihr Portfolio ,